Tissue Microarrays: Construction and Uses

  • Carol B. Fowler
  • Yan-Gao Man
  • Shimin Zhang
  • Timothy J. O’Leary
  • Jeffrey T. Mason
  • Robert E. Cunningham
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 724)

Abstract

Tissue microarrays (TMAs) are produced by taking small punches from a series of paraffin-embedded (donor) tissue blocks and transferring these tissue cores into a positionally encoded array in a recipient paraffin block. Though TMAs are not used for clinical diagnosis, they have several advantages over using conventional whole histological sections for research. Tissue from multiple patients or blocks can be examined on the same slide, and only a very small amount of reagent is required to stain or label an entire array. Multiple sections (100–300) can be cut from a single array block, allowing for hundreds of analyses per microarray. These advantages allow the use of TMAs in high-throughput procedures, such as screening antibodies for diagnostics and validating prognostic markers that are impractical using conventional whole tissue sections. TMAs can be used for immunohistochemistry, immunofluorescence, in situ hybridization, and conventional histochemical staining. Finally, several tissue cores may be taken without ­consuming the tissue block, allowing the donor block to be returned to its archive for any additional studies.

Key words

Fluorescence in situ hybridization Formalin-fixed paraffin-embedded Hematoxylin and eosin HER-2 gene Tissue microarray TMA 

References

  1. 1.
    Wan, W. H., Fortuna, M. B., and Furmanski, P. (1987) A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 103, 121–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4, 844–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Camp, R. L., Charette, L. A., and Rimm, D. L. (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest. 80, 1943–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Cryan, J., O’Grady, A., Allen, D., and Kay, E. (2009) Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer. Histopathology 54, 901.PubMedCrossRefGoogle Scholar
  5. 5.
    Cunningham, R. E., Abbondanzo, S. L., Chu, W. S., Emory, T. S., Sobin, L. H., and O’Leary, T. J. (2001) Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol. 9, 19–23.PubMedCrossRefGoogle Scholar
  6. 6.
    Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., et al. (2001) Delineation of prognostic ­biomarkers in prostate cancer. Nature 412, 822–6.PubMedCrossRefGoogle Scholar
  7. 7.
    Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Kollermann, J., Minner, S., et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 21, 1371–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Fernandes, A. P., Capitanio, A., Selenius, M., Brodin, O., Rundlof, A. K., and Bjornstedt, M. (2009) Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology 55, 313–20.PubMedCrossRefGoogle Scholar
  9. 9.
    Eguíluz, C., Viguera, E., Millán, L., and Pérez, J. (2006) Multitissue array review: a chronological description of tissue array techniques, applications and procedures. Pathol Res Pract. 202, 561–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Carlson, R. W., Moench, S. J., Hammond, M. E., Perez, E. A., Burstein, H. J., Allred, D. C., et al. (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 4 Suppl 3, S1–22.Google Scholar
  11. 11.
    Dandachi, N., Dietze, O., and Hauser-Kronberger, C. (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 82, 1007–14.PubMedGoogle Scholar
  12. 12.
    Graham, A. D., Faratian, D., Rae, F., and Thomas, J. S. (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52, 847–55.PubMedCrossRefGoogle Scholar
  13. 13.
    Faratian, D., Graham, A., Rae, F., and Thomas, J. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54, 428–32.PubMedCrossRefGoogle Scholar
  14. 14.
    Camp, R. L., Chung, G. G., and Rimm, D. L. (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 8, 1323–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu, C. L., Prapong, W., Natkunam, Y., Alizadeh, A., Montgomery, K., Gilks, C. B., et al. (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 161, 1557–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Allen, T. C. (1992) Hematoxylin and Eosin. In E. B. Prophet, B. Mills, J. B. Arrington, and L. H. Sobin, ed. AIFP Laboratory Methods in Histotechnology, Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC, 53–58.Google Scholar
  17. 17.
    Sauter, G., Simon, R., and Hillan, K. (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2, 962–72.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Carol B. Fowler
    • 1
  • Yan-Gao Man
    • 1
  • Shimin Zhang
    • 1
  • Timothy J. O’Leary
    • 2
  • Jeffrey T. Mason
    • 1
  • Robert E. Cunningham
    • 1
  1. 1.Armed Forces Institute of PathologyWashingtonUSA
  2. 2.Veterans Health AdministrationWashingtonUSA

Personalised recommendations